Electroconvulsive therapy (ECT) is one of the most effective treatments available for depression, particularly when medications have failed. Between 70% and 90% of patients with treatment-resistant depression respond to ECT, and roughly 50% to 70% achieve full remission. For comparison, standard antidepressants achieve remission in only about 13% of treatment-resistant cases. That gap in effectiveness is enormous, and it’s why ECT remains a cornerstone of psychiatric care despite its complicated reputation.
Response and Remission Rates
There’s an important distinction between “response” and “remission.” Response means symptoms improve by at least 50%. Remission means symptoms are essentially gone. In clinical studies, the overall response rate for ECT in treatment-resistant depression reaches about 86%, and full remission rates land between 50% and 70%. Those numbers hold up across decades of research. The overwhelming majority of trials comparing ECT directly to antidepressants have shown ECT to be superior.
Older patients tend to respond even better than younger ones. A longitudinal study found that patients over 30 achieved remission in a median of 5 sessions, compared to 7 for younger patients. Older adults also showed greater improvement in anxiety and physical symptoms. This is particularly relevant because depression in older adults often involves more somatic complaints and can be harder to treat with medication alone.
What a Course of Treatment Looks Like
A typical course of ECT involves sessions two or three times per week. Patients who achieve remission need an average of about 13 to 14 sessions, while those who don’t respond typically receive 18 or more before the treatment is stopped. Each session takes place under general anesthesia and lasts only a few minutes. You’re usually in the treatment facility for a few hours total, including recovery time.
Clinicians often evaluate progress after the first few sessions. Research has shown that improvement after just two sessions is a strong predictor of whether someone will eventually reach full remission. If there’s no improvement after 10 sessions, the likelihood of a meaningful response drops significantly. A minimum of 10 sessions is generally required before someone is considered a non-responder.
How ECT Works in the Brain
The honest answer is that the full mechanism isn’t completely understood, but researchers have identified several important effects. ECT influences the release, reuptake, and receptor sensitivity of key mood-regulating brain chemicals, including serotonin, norepinephrine, and dopamine. It also promotes neuroplasticity, essentially encouraging the brain to grow new cells and form new connections, particularly in the hippocampus, a region critical for mood regulation and memory.
Brain imaging studies have shown that ECT changes the structural wiring between frontal and emotional processing regions of the brain. These are the same circuits that function abnormally in severe depression. The combination of chemical changes and structural rewiring likely explains why ECT works faster and more powerfully than medications, which primarily target only one or two brain chemicals.
Memory and Cognitive Side Effects
Memory loss is the side effect people worry about most, and it’s a legitimate concern. About 60% of patients report some memory problems, with 40% saying those problems last from several weeks to several years. The most common issue is loss of autobiographical memory, meaning memories of events you personally experienced. This loss is typically worst for the period immediately before treatment but can sometimes extend back up to a year or, in rare cases, longer.
Most cognitive side effects improve significantly within six months. However, objective testing has shown that some autobiographical memory loss persists for at least a year, and it’s unlikely that memories lost at that point will return spontaneously. The severity varies widely between individuals, though studies have rarely attempted to identify who is most at risk for particularly severe loss.
The type of ECT matters. There are two main electrode placements: bilateral (both sides of the head) and right unilateral (one side only). When right unilateral ECT is delivered at adequate energy levels, it matches bilateral ECT in effectiveness for depression. But patients receiving right unilateral treatment experience significantly less confusion, better preservation of verbal memory, and less autobiographical memory loss. The cognitive advantage of right unilateral placement is clear enough that it’s often the preferred starting approach.
When ECT Is Recommended
ECT isn’t reserved exclusively for people who have “tried everything else.” Clinical guidelines recognize it as a first-line treatment in several emergency situations: active suicidal intent, refusal to eat or drink, catatonia, severe psychotic depression, and situations requiring the fastest possible symptom relief. For peripartum depression and depression with psychotic features (delusions or hallucinations), ECT is considered especially appropriate.
That said, the most common path to ECT is through treatment resistance, typically after two or more adequate trials of antidepressant medication haven’t worked. A history of good response to ECT in a past episode is one of the strongest predictors that it will work again.
The Relapse Problem
ECT’s biggest limitation isn’t its short-term effectiveness. It’s what happens afterward. Without ongoing treatment, relapse rates are high. One study found that 28% of patients relapsed within 6 months and 41% within a year. Patients with non-psychotic depression fared worse, with 53% relapsing at 6 months and 73% at one year, compared to only 12% and 21% for patients whose depression included psychotic features.
This is why maintenance treatment after ECT is critical. The most effective strategy for preventing relapse combines ongoing ECT sessions (gradually spaced further apart) with medication. One retrospective study found that patients receiving both maintenance ECT and medication had a 93% chance of remaining well at two years, compared to just 52% for those on medication alone. At five years, the combined group still had a 73% relapse-free survival rate versus only 18% for medication alone.
Interestingly, one randomized trial found that cognitive behavioral therapy combined with medication outperformed maintenance ECT combined with medication for sustaining response, with 65% maintaining their improvement at one year versus 28% in the maintenance ECT group. This suggests that once the acute crisis is resolved by ECT, psychological therapy may play a particularly valuable role in keeping people well. The best maintenance plan likely depends on the individual, their severity, and what’s practically available to them.